The funding round was led by DSW Ventures with participation from XTX Ventures, Cambridge Technology Capital, angel investors, and Innovate UK.
"Our machine could pick up cancer, HIV or sepsis earlier – any disease with a nucleic acid trace. We’re made of DNA – that’s the source code. If you can pick up traces of faults and errors in that code, you can detect problems across the board before symptoms appear. We’ve built the ultimate needle-in-a-haystack detector – a tool that we can put in the hands of scientists to enable the discoveries of tomorrow."
Twin Path Ventures led the pre-seed round to accelerate the rollout of the artificial intelligence game creation platform.
"We want to empower creatives and storytellers to embrace the potential of AI-supported narrative game creation. It’s the future of gamemaking, and we’re at the forefront of making its possibilities a reality."
Plural led the Series A round to help the London based startup expand its team and scale its super-brain solution.
"This funding is yet another milestone for Oriole following a year of rapid pace and growth. This is a booming market desperate for solutions and our ambition is to create an ecosystem of photonic networking that can reshape this industry by solving today's bottlenecks and enabling greater competition at the GPU layer. Building on decades of research, we're paving the way for faster, more efficient, more sustainable AI."
ETFS Capital led the Series B financing, with participation from XTX Ventures, to support international expansion and product development.
"With the digital evolution of credit now inevitable, we are pleased to have ETFS join our team given their deep experience in capital markets innovation. Building the best-in-class dataset for one of the world's largest asset classes remains an ambitious task, and we are excited about the opportunities ahead of us."
Hargreave Hale AIM VCT led the financing round to help accelerate the company platform and expand into new disease areas.
"The close of our Series A round marks the 'end of the beginning' and the start of a new chapter for Qureight, as we turn our focus to developing our platform and creating products in new disease areas. Our mission to extend the lives of lung and heart disease patients will be bolstered by the invaluable expertise of our new board and new senior team members, and we are looking forward to adding to our strategic biopharma collaborations."
